Immunogenicity Without a Comparative Efficacy Trial: Where Biosimilar Immunogenicity Data Now Comes From
Introduction Evaluating immunogenicity without a comparative efficacy trial relies on replacing Phase III clinical efficacy studies with orthogonal bioanalytical characterization, […]


